MDxHealth SA is a Belgium-based healthcare company which provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The Company's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States.
企業コードMDXH
会社名MDxHealth SA
上場日Jun 26, 2006
最高経営責任者「CEO」Mr. Michael K. McGarrity
従業員数312
証券種類Ordinary Share
決算期末Jun 26
本社所在地CAP Business Center
都市HERSTAL
証券取引所NASDAQ Capital Market Consolidated
国Belgium
郵便番号4040
電話番号3243642070
ウェブサイトhttps://mdxhealth.com/
企業コードMDXH
上場日Jun 26, 2006
最高経営責任者「CEO」Mr. Michael K. McGarrity
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし